Potency of an experimental DNA vaccine against Aujeszky's disease in pigs.
Intradermal vaccination with plasmid DNA encoding envelope glycoprotein C (gC) of pseudorabies virus (PrV) conferred protection of pigs against Aujeszky's disease when challenged with strain 75V19, but proved to be inadequate for protection against the highly virulent strain NIA-3. To improve the performance of the DNA vaccine, animals were vaccinated intradermally with a combination of plasmids expressing PrV glycoproteins gB, gC, gD, or gE under control of the major immediate-early promotor/enhancer of human cytomegalovirus. 12.5 microg per plasmid were used per immunization of 5-week old piglets which were injected three times at biweekly intervals. Five out of six animals survived a lethal challenge with strain NIA-3 without exhibiting central nervous signs, whereas all the control animals succumbed to the disease. This result shows the increased protection afforded by administration of the plasmid mixture over vaccination with a gC expressing plasmid alone. A comparative trial was performed using commercially available inactivated and modified-live vaccines and a mixture of plasmids expressing gB, gC, and gD. gE was omitted to conform with current eradication strategies based on gE-deleted vaccines. All six animals vaccinated with the live vaccine survived the lethal NIA-3 challenge without showing severe clinical signs. In contrast, five of six animals immunized with the inactivated vaccine died, as did two non-vaccinated controls. In this test, three of six animals vaccinated with the DNA vaccine survived without severe clinical signs, whereas three succumbed to the disease. Comparing weight reduction and virus excretion, the DNA vaccine also ranged between the inactivated and modified-live vaccines. Thus, administration of DNA constructs expressing different PrV glycoproteins was superior to an adjuvanted inactivated vaccine but less effective than an attenuated live vaccine in protection of pigs against PrV infection. Our data suggest a potential use of DNA vaccination in circumstances which do not allow administration of live attenuated vaccines.
Gerdts
V
V
Institute of Molecular and Cellular Virology, Friedrich-Loeffler-Institutes, Federal Research Centre for Virus Diseases of Animals, Insel Riems, Germany.
Jöns
A
A
Mettenleiter
T C
TC
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002460:Cell Line; D002522:Chlorocebus aethiops; D003001:Cloning, Molecular; D003587:Cytomegalovirus / Q000235:genetics; D004742:Enhancer Elements, Genetic; D015752:Genes, env; D011558:Herpesvirus 1, Suid / Q000235:genetics / Q000276:immunology / Q000472:pathogenicity*; D006801:Humans; D007668:Kidney; D011401:Promoter Regions, Genetic; D011557:Pseudorabies / Q000276:immunology* / Q000517:prevention & control; D022421:Pseudorabies Vaccines; D013552:Swine; D013997:Time Factors; D019444:Vaccines, DNA; D014709:Vero Cells; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines; D014774:Virulence; D017201:Virus Shedding
D000914:Antibodies, Viral; D022421:Pseudorabies Vaccines; D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; D014765:Viral Vaccines